Abstract: Tuberculosis remains the leading cause of mortality worldwide. The second line of anti-TB drug Nucleoside analogs has been introduced in several compounds to improve their anti-TB activity against mycobacterium as well as their multidrug-resistant strains. Several Nucleoside analogs have shown very good activity. A series of Nucleoside analogs have been evaluated for their activity against M. tuberculosis. Some Nucleoside analogs exhibited significant activity when compared with first-line drugs and could be a good starting point to develop new lead compounds in the fight against multi-drug resistant tuberculosis.